SUN-682 Prevalence of Eating Disorders Among GLP-1 Receptor Agonist Users: A Cross-Sectional Analysis

Abstract Disclosure: H. Shalabi: None. Introduction: The use of glucagon-like peptide-1 (GLP-1) receptor agonists for obesity management has increased substantially due to their effectiveness in promoting weight loss. However, the psychological effects of these medications, particularly regarding their potential influence on eating disorders, remain insufficiently understood. This study examines the prevalence of eating disorder-like behaviors among GLP-1 receptor agonist users to provide insights into the psychological considerations of this treatment approach. Methods: This cross-sectional survey included 660 participants aged 40-60 years, 67.7% female and 32.3% male. Participants reported demographic data, weight-loss treatment history, and self-reported eating behaviors, including binge eating episodes, feelings of guilt after eating, and fear of weight gain. Comparisons were made between GLP-1 receptor agonist users (current or past) and non-users to identify trends and associations. Statistical analysis was conducted to explore group differences and potential risk factors for disordered eating behaviors. Results: Among the participants, 43.9% reported current or past GLP-1 receptor agonist use. Key findings include:•Binge eating episodes: 6.9% of GLP-1 users.•Guilt after eating: 24.1% of users.•Fear of weight gain: 37.9% of users.GLP-1 users exhibited similar levels of dietary restraint and food preoccupation compared to non-users, suggesting shared psychological characteristics. These findings highlight the need to explore whether GLP-1 receptor agonists contribute to such behaviors or if these behaviors stem from preexisting psychological profiles of users. Conclusions: This study reveals a significant overlap between the use of GLP-1 receptor agonists and eating disorder-like behaviors. It emphasizes the importance of incorporating routine psychological assessments into obesity management protocols involving GLP-1 therapy. A collaborative, multidisciplinary approach—integrating endocrinologists, psychologists, and nutritionists—is vital for addressing both the physical and mental health needs of patients. Further longitudinal research is essential to determine causality, optimize treatment strategies, and enhance patient outcomes by integrating pharmacological and behavioral health interventions. Presentation: Sunday, July 13, 2025